Physician profile
Manish Singla
NPI 1912089202
$18,450.16
in general payments reported to CMS, 2019-2025
31 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.66 · 2022: $985 · 2023: $734 · 2024: $15K · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,931 · Travel and Lodging: $1,489 · Education: $19.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,000.00 |
| Food and Beverage | $4,931.40 |
| Travel and Lodging | $1,489.43 |
| Education | $19.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13,361.86 | 2024-2025 | Voquezna |
| Abbvie INC. | $995.31 | 2022-2025 | Linzess, Rinvoq, Viberzi |
| Celgene Corporation | $589.77 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $587.64 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $507.24 | 2022-2025 | Tremfya, Stelara |
| Pfizer INC. | $410.41 | 2022-2025 | |
| Lilly USA, LLC | $242.97 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.23 | 2023-2025 | Xifaxan, Plenvu |
| Fujifilm Healthcare Americas Corporation | $195.67 | 2022 | |
| Medtronic, INC. | $189.78 | 2022 | |
| Boston Scientific Corporation | $166.69 | 2024-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Cre Pro |
| Genzyme Corporation | $161.29 | 2022-2025 | |
| Qol Medical, LLC | $124.67 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $83.93 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $62.98 | 2024-2025 | Vegzelma, Zymfentra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $60.65 | 2024-2025 | Dupixent |
| Daiichi Sankyo INC. | $57.69 | 2024-2025 | Injectafer |
| Fresenius Kabi USA, LLC | $53.83 | 2023-2024 | Idacio |
| Intercept Pharmaceuticals, INC. | $52.24 | 2024-2025 | |
| Novo Nordisk INC | $44.50 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $36.16 | 2024-2025 | |
| Stryker Corporation | $32.89 | 2025 | Neptune |
| Integra Lifesciences Corporation | $31.41 | 2022-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Echosens North America, INC. | $28.98 | 2023 | Fibroscan |
| Pharmacosmos Therapeutics INC. | $27.97 | 2025 | Monoferric |
| Braintree Laboratories, INC. | $24.43 | 2025 | Suflave, Sutab |
| Pacira Pharmaceuticals Incorporated | $22.26 | 2023 | Exparel |
| Alnylam Pharmaceuticals INC. | $20.68 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.74 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $15.09 | 2024 | Dificid |
| Thd America, INC. | $13.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.